Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy.
Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy. Nutr Cancer. 2018 Oct 01;:1-6 Authors: Espeli V, Vergotte S, Dietrich PY, Pichard C, Siano M Abstract To compare safety and effectiveness of prolonged (>28 days) versus short duration (≤28 days) use of nasogastric tube for enteral nutrition and weight loss prevention during curative radiotherapy with or without concurrent chemotherapy or cetuximab for head and neck cancer patients. We performed a retrospective study and database review of all patients at our center, treated with radiotherapy for head and neck cancer receiving enteral nutrition by nasogastric tube. Type of treatment, weight and body mass index changes, and related complications (gastroesophageal reflux, pneumonia, ulcer, feeding tube obstruction, or dislocation) were documented. Comparison between patients with prolonged (>28 days, group A) and short duration (≤28 days, group B) of EN through nasogastric tube was performed. Data expressed as mean ± SD or median (min; max) values as appropriate, and analyzed by ANOVA repeated measures and Kaplan-Meier estimates. We identified 114 patients who fulfilled the inclusion criteria. Among them, 10% were treated with radiotherapy alone, while 90% received concurrent chemotherapy or cetuximab. Ninety-four patients (82%, group A) had a nasogastric tube in place for a ...
Condition: Malignant Neoplasm Interventions: Drug: Fentanyl Sublingual Spray; Drug: Morphine; Other: Physical Performance Testing; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Conditions: D011471; D064129; D035683; D009360; D014408 Intervention: Diagnostic Test: Periodic ARV7 and miRNA evaluation Sponsor: Azienda Ospedaliero-Universitaria Careggi Recruiting
Condition: Locally Advanced Colon Cancer Intervention: Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor: Universidad de León Recruiting
Condition: Patients With Metastatic Colorectal Cancer Interventions: Drug: Fluoropyrimidine; Drug: Bevacizumab Sponsor: Centre Hospitalier Universitaire Dijon Not yet recruiting
Condition: Breast Cancer Interventions: Drug: Avelumab; Drug: Aspirin; Drug: Lansoprazole Sponsors: The Christie NHS Foundation Trust; University of Manchester Not yet recruiting
Conditions: Nutrition; Physical Activity Interventions: Behavioral: Intervention Physical Activity; Other: Usual Care Sponsors: University of North Carolina, Chapel Hill; University of Texas Completed
Conditions: Neutropenia; Breast Cancer Interventions: Drug: Eflapegrastim; Drug: Docetaxel; Drug: Cyclophosphamide Sponsor: Spectrum Pharmaceuticals, Inc Not yet recruiting
Conditions: Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; Healthy Intervention: Sponsor: Indiana University Recruiting
Conditions: Neutropenia, Febrile; Leukemia; Pediatric Cancer; Antibiotic Reaction Interventions: Drug: Ceftazidime Injection; Drug: Cefepime Injection Sponsor: Indonesia University Completed
Condition: Cancer Anaemia Intervention: Drug: Ferinject Sponsor: Samsung Medical Center Recruiting